Rubin Michael P.'s Form 4 filing
Kyverna Therapeutics, Inc.KYTX · filed Feb 12, 2024
- Accession no.
- 0000950170-24-014000
- Filed
- Feb 12, 2024, 5:51 PM ET
- Trade date
- Feb 12, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $9.90M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rubin Michael P.CIK 0001867627 | Other: Former 10% Owner |
| Northpond Ventures III, LPCIK 0001972690 | Other: Former 10% Owner |
| Northpond Ventures III GP, LLCCIK 0002010695 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | Common Stock | CConversionAcquired | +2,805,426 | –F1 | – | 2,805,426 | Indirect | |
| Feb 12, 2024 | Common Stock | PPurchaseAcquired | +450,000 | $22.00 | +$9,900,000 | 450,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | Common Stock | CConversionDisposed | −2,805,426 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the "Series B Preferred Stock"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock"). The Series B Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.